Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 718 of 5804
-
Weight-Loss drug for kids? new trial tests liraglutide in children as young as 6
Disease control OngoingThe study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either ge…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for GVHD patients who failed other treatments
Disease control Recruiting nowThis is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lupus drug sirolimus shows promise in phase 3 trial
Disease control OngoingThis is a multi-center, double-blinded, randomized, placebo-controlled, phase 3 study to evaluate the efficacy and safety of sirolimus administered in addition to standard therapy, in patients with active SLE disease.
Phase: PHASE3 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Should High-Risk CLL patients start treatment early? major trial aims to find out
Disease control Recruiting nowThis phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug cocktail shows promise against tough head and neck cancer
Disease control CompletedThe primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck (SCCHN) on the basis of confirmed object…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cocktail aims to boost remission in rare blood cancer
Disease control OngoingThis is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC bendamustine and rituximab for 6 28-day cycles. Bendamustine will be given intravenously…
Phase: PHASE2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo aims to block prostate cancer return in High-Risk men
Disease control OngoingThis phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and mai…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail shows promise against tough breast cancer
Disease control OngoingThis phase I/II trial studies the side effects and best dose of copanlisib and how well it works when given together with eribulin in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metas…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Poop pills could stop deadly transplant complication
Disease control Recruiting nowTo evaluation the efficacy and safety of autologous fecal bacteria transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation. Bone marrow transplant patients were recruited.
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Massive stroke drug study shows Real-World results
Disease control CompletedThe aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
Sponsor: Supergene, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for advanced stomach cancer: drug combo targets patients who failed first-line therapy
Disease control Recruiting nowThis study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included…
Phase: PHASE2 • Sponsor: Shandong Tumor Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a simple injection save Kids' hearing during chemo?
Disease control Recruiting nowA Phase 3 multi-institutional study for treatment of children with newly diagnosed hepatoblastoma using a modified Paediatric Hepatic International Tumour Trial (PHITT) strategy incorporating a randomized assessment of sodium thiosulfate as auditory protection for children with l…
Phase: PHASE3 • Sponsor: Shanghai Children's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
BREAST CANCER TRIAL TESTS IF LESS AXILLARY TREATMENT IS SAFE AFTER CHEMO
Disease control Recruiting nowThe aim of this study is to assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inf…
Phase: NA • Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a heart drug save lives in septic shock? new trial aims to find out.
Disease control OngoingSeptic shock is a major health problem, with several million cases annually worldwide and a mortality approaching 45%. Tachycardia is associated with excess mortality during septic shock. This pejorative effect could be related to the increase in cardiac metabolic demand, impaire…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental drug shows promise for rare amyloidosis
Disease control CompletedThis is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy. Approximately 35 subjects will receive therapy with belantamab mafodotin. Subject participation will include a Screening Phase, a…
Phase: PHASE2 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Jun 26, 2026 13:31 UTC
-
Targeted drug before surgery shows promise for RET-Altered thyroid cancer
Disease control OngoingThis phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material \[deoxyribonucleic acid (DNA)\]). Selpercatinib may stop the growth of tumor cells by blocking …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for breast cancer patients when first treatment fails
Disease control Recruiting nowThe study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cell therapy takes on advanced kidney cancer
Disease control OngoingThis is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the ma…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental cell therapy takes on Hard-to-Treat myeloma
Disease control CompletedThe purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Phase: PHASE1 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC